ES8303293A1 - Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (Z), their preparation and their use as medicines in the treatment of disorders of the central nervous system. - Google Patents
Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (Z), their preparation and their use as medicines in the treatment of disorders of the central nervous system.Info
- Publication number
- ES8303293A1 ES8303293A1 ES512842A ES512842A ES8303293A1 ES 8303293 A1 ES8303293 A1 ES 8303293A1 ES 512842 A ES512842 A ES 512842A ES 512842 A ES512842 A ES 512842A ES 8303293 A1 ES8303293 A1 ES 8303293A1
- Authority
- ES
- Spain
- Prior art keywords
- aryl
- atom
- alkyl group
- lower alkyl
- nervous system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention concerns new derivatives of 1-aryl 2-aminomethyl cyclopropane carboxamides (Z) of general formula I: < IMAGE > (I) in which: R represents a hydrogen or halogen atom, a lower alkyl group, a lower alkoxy group, or a hydroxy. nitro or amino group n represents the value 1 or 2 R1 and R2 represent a hydrogen atom, a lower alkyl group, an aryl or lower alkaryl group, possibly substituted, preferably in para position, by a halogen atom, preferably a chlorine atom R1 and R2 may also form a heterocycle having 5 or 6 members with the adjacent nitrogen atom R3 and R4 represent a hydrogen atom or a lower alkyl group R3 and R4 may also form with the adjacent nitrogen atom a heterocycle having 5 or 6 members, possibly containing an additional heteroatom selected from among nitrogen and oxygen, as well as their salts with therapeutically acceptable inorganic or organic acids, and their pharmaceutical compositions and use in the treatment of central nervous system disturbances, e.g., depression.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR8112312A FR2508035A1 (en) | 1981-06-23 | 1981-06-23 | ARYL-1-AMINOMETHYL-2 CYCLOPROPANES CARBOXAMIDE (Z) DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS USEFUL IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS |
Publications (2)
Publication Number | Publication Date |
---|---|
ES8303293A1 true ES8303293A1 (en) | 1983-03-01 |
ES512842A0 ES512842A0 (en) | 1983-03-01 |
Family
ID=9259785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES512842A Granted ES512842A0 (en) | 1981-06-23 | 1982-06-04 | "PROCEDURE FOR PREPARING CARBOXAMIDIC DERIVATIVES". |
Country Status (11)
Country | Link |
---|---|
US (1) | US4478836A (en) |
EP (1) | EP0068999B1 (en) |
JP (1) | JPS584752A (en) |
AT (1) | ATE13422T1 (en) |
AU (1) | AU550774B2 (en) |
CA (1) | CA1202639A (en) |
DE (1) | DE3263734D1 (en) |
ES (1) | ES512842A0 (en) |
FR (1) | FR2508035A1 (en) |
LU (1) | LU90410I2 (en) |
ZA (1) | ZA824453B (en) |
Families Citing this family (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2581059B1 (en) * | 1985-04-25 | 1988-04-22 | Pf Medicament | PROCESS FOR THE PREPARATION OF PHENYL-1 HYDROCHLORIDE DIETHYL AMINO CARBONYL-1 AMINOMETHYL-2 CYCLOPROPANE (Z) |
FR2581060B1 (en) * | 1985-04-25 | 1988-07-01 | Pf Medicament | INDUSTRIAL PROCESS FOR OBTAINING MIDALCIPRAN |
WO1995022521A1 (en) * | 1994-02-22 | 1995-08-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Aminoalkylcyclopropane derivative |
CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug response by a serotonin 1A receptor antagonist |
AU6776196A (en) * | 1995-08-16 | 1997-03-12 | Eli Lilly And Company | Potentiation of serotonin response |
FR2752732B1 (en) * | 1996-08-28 | 1998-11-20 | Pf Medicament | EXTENDED RELEASE GALENIC FORM OF MILNACIPRAN |
CN105712985A (en) * | 2001-10-12 | 2016-06-29 | 阿泽范药品公司 | Beta -LACTAMYL VASOPRESSIN Vla ANTAGONISTS |
US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
US6602911B2 (en) | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
CN1662231A (en) * | 2002-04-24 | 2005-08-31 | 柏树生物科学公司 | Prevention and treatment of functional somatic disorders, including stress-related disorders |
EP1578719A4 (en) * | 2002-10-25 | 2006-07-05 | Collegium Pharmaceutical Inc | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
WO2004075886A1 (en) * | 2003-02-14 | 2004-09-10 | Pierre Fabre Medicament | Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament |
FR2851163B1 (en) * | 2003-02-14 | 2007-04-27 | USE OF DEXTROGYAN ENANTIOMER OF MILNACIPRAN FOR THE PREPARATION OF A MEDICINAL PRODUCT | |
MXPA05011225A (en) * | 2003-04-18 | 2005-12-14 | Pharmacia & Upjohn Co Llc | Combination therapies for chronic obstructive pulmonary disease (copd). |
AU2004265020B8 (en) * | 2003-08-15 | 2009-11-05 | H. Lundbeck A/S | Cyclopropyl derivatives as NK3 receptor antagonists |
ZA200601175B (en) * | 2003-08-15 | 2007-04-25 | Lundbeck & Co As H | Cyclopropyl derivatives as NK3 receptor antagonists |
EP1691811B1 (en) | 2003-12-11 | 2014-07-23 | Sunovion Pharmaceuticals Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
EP1737473A4 (en) * | 2004-04-19 | 2009-08-26 | Noven Therapeutics Llc | Lithium combinations, and uses related thereto |
US9597314B2 (en) | 2005-03-22 | 2017-03-21 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids for treating premenstrual disorders |
EP1871358A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists |
WO2006116150A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
BRPI0610037A2 (en) * | 2005-04-22 | 2010-05-25 | Wyeth Corp | dihydrobenzofuran derivatives and their use |
CA2611724C (en) * | 2005-06-10 | 2014-07-29 | Pierre Fabre Medicament S.A. | Stabilized milnacipran formulation |
EP1904843A2 (en) | 2005-07-08 | 2008-04-02 | Braincells, Inc. | Methods for identifying agents and conditions that modulate neurogenesis |
AU2006270039B2 (en) | 2005-07-19 | 2013-07-04 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
WO2007025144A1 (en) * | 2005-08-24 | 2007-03-01 | University Of Illinois - Chicago | 5-ht2c receptor agonists as anorectic agents |
US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
CA2625153A1 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
US20070112017A1 (en) | 2005-10-31 | 2007-05-17 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
EP1980271A4 (en) * | 2006-01-27 | 2012-04-25 | Asahi Kasei Pharma Corp | Medicine for transnasal administration |
US20080319083A1 (en) * | 2006-01-27 | 2008-12-25 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
FR2912057B1 (en) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | PHARMACEUTICAL COMPOSITION COMPRISING SAREDUTANT AND A SELECTIVE SEROTONIN RECAPTURE INHIBITOR OR SEROTONIN / NOREPINEPHRINE RECAPTURE INHIBITOR |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
EP1998773A2 (en) * | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | New therapeutic combinations for the treatment of depression |
US7678808B2 (en) | 2006-05-09 | 2010-03-16 | Braincells, Inc. | 5 HT receptor mediated neurogenesis |
US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
WO2008030651A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
US20100016274A1 (en) * | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
US20080171750A1 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation Of Neurogenesis With Use of Modafinil |
WO2008104957A2 (en) * | 2007-02-28 | 2008-09-04 | Ranbaxy Laboratories Limited | Novel polymorphic forms of milnacipran hydrochloride |
US20090048233A1 (en) * | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination |
US20090069431A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched milnacipran |
WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
WO2010021681A2 (en) * | 2008-08-18 | 2010-02-25 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
WO2010036773A1 (en) * | 2008-09-24 | 2010-04-01 | Concert Pharmaceuticals, Inc. | Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives |
FR2941454B1 (en) | 2009-01-29 | 2011-04-01 | Pf Medicament | PROCESS FOR THE SYNTHESIS OF (1S, 2R) -MILNACIPRAN |
US20100216805A1 (en) | 2009-02-25 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US20100274050A1 (en) * | 2009-04-23 | 2010-10-28 | Glenmark Generics Limited | Solid milnacipran and process for the preparation of the same |
US20100286260A1 (en) * | 2009-05-05 | 2010-11-11 | Forest Laboratories Holdings Ltd. | Milnacipran formulations |
WO2011016057A2 (en) | 2009-08-05 | 2011-02-10 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
CA2779711C (en) | 2009-11-06 | 2016-11-01 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
WO2011092065A1 (en) | 2010-01-29 | 2011-08-04 | Nicox S.A. | Nitric oxide releasing compounds for the treatment of neurophatic pain |
CN103269584B (en) | 2010-07-01 | 2017-05-03 | 阿泽凡药物公司 | Methods for treating post traumatic stress disorder |
JP2013536832A (en) | 2010-08-30 | 2013-09-26 | ルピン・リミテッド | Milnacipran controlled release pharmaceutical composition |
US20120289744A1 (en) | 2010-11-03 | 2012-11-15 | Arch Pharmalabs Limited | Process for preparing optically pure milnacipran and its pharmaceutically acceptable salts |
US20140045936A1 (en) | 2011-04-21 | 2014-02-13 | Wake Forest University Health Sciences | Cyclopropyl derivatives and methods of use |
WO2014009767A1 (en) | 2012-07-07 | 2014-01-16 | Micro Labs Limited | An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts |
WO2014203277A2 (en) * | 2013-06-19 | 2014-12-24 | Msn Laboratories Private Limited | Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride |
WO2015044962A1 (en) | 2013-09-30 | 2015-04-02 | Cadila Healthcare Limited | Amorphous form of levomilnacipran hydrochloride and hydrates thereof |
MX2016012645A (en) | 2014-03-28 | 2017-01-11 | Azevan Pharmaceuticals Inc | Compositions and methods for treating neurodegenerative diseases. |
WO2019055913A1 (en) | 2017-09-15 | 2019-03-21 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating brain injury |
BR112022000992A2 (en) | 2019-07-19 | 2022-06-14 | Arx Llc | Non-sedating dexmedetomidine treatment regimens |
US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA570688A (en) * | 1959-02-17 | E. Speeter Merrill | Antispasmodic substituted amines | |
CA619080A (en) * | 1961-04-25 | The Upjohn Company | N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES | |
GB1415541A (en) | 1972-11-30 | 1975-11-26 | Hexachimie | 1-amino-methyl-2,2-diarylcyclopropanecarboxamide |
-
1981
- 1981-06-23 FR FR8112312A patent/FR2508035A1/en active Granted
-
1982
- 1982-06-04 ES ES512842A patent/ES512842A0/en active Granted
- 1982-06-21 AT AT82401129T patent/ATE13422T1/en active
- 1982-06-21 EP EP82401129A patent/EP0068999B1/en not_active Expired
- 1982-06-21 DE DE8282401129T patent/DE3263734D1/en not_active Expired
- 1982-06-22 CA CA000405651A patent/CA1202639A/en not_active Expired
- 1982-06-22 AU AU85086/82A patent/AU550774B2/en not_active Expired
- 1982-06-22 US US06/390,810 patent/US4478836A/en not_active Expired - Lifetime
- 1982-06-23 ZA ZA824453A patent/ZA824453B/en unknown
- 1982-06-23 JP JP57109097A patent/JPS584752A/en active Granted
-
1999
- 1999-06-30 LU LU90410C patent/LU90410I2/en unknown
Also Published As
Publication number | Publication date |
---|---|
FR2508035A1 (en) | 1982-12-24 |
AU8508682A (en) | 1983-01-06 |
AU550774B2 (en) | 1986-04-10 |
CA1202639A (en) | 1986-04-01 |
EP0068999A1 (en) | 1983-01-05 |
FR2508035B1 (en) | 1984-06-29 |
ATE13422T1 (en) | 1985-06-15 |
ZA824453B (en) | 1983-04-27 |
JPS6323186B2 (en) | 1988-05-16 |
DE3263734D1 (en) | 1985-06-27 |
ES512842A0 (en) | 1983-03-01 |
US4478836A (en) | 1984-10-23 |
EP0068999B1 (en) | 1985-05-22 |
LU90410I2 (en) | 1999-08-31 |
JPS584752A (en) | 1983-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES8303293A1 (en) | Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (Z), their preparation and their use as medicines in the treatment of disorders of the central nervous system. | |
ATE127801T1 (en) | PYRAZOLOPYRIDINE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF. | |
GR3000571T3 (en) | Amide derivatives | |
UA27238C2 (en) | Indoline derivatives, their pharmaceutical acceptable salts which are antagonists of vasopressin vi-receptors, method for their synthesis, intermediate compounds and pharmaceutical composition | |
ATE28565T1 (en) | SPIRO(4.(3+N))-2-AZA-ALKAN-3-CARBONIC ACID DERIVATIVES, PROCESS FOR THEIR PRODUCTION, AGENTS CONTAINING THIS AND THEIR USE. | |
DK519985D0 (en) | QUINOLONCARBOXYLIC ACID DERIVATIVES, PROCEDURES FOR PREPARING THEREOF AND ANTIBACTERIAL SUBSTANCES CONTAINING SUCH DERIVATIVES | |
DK0526313T3 (en) | New urea derivatives, their preparation and therapeutic use | |
ATE48001T1 (en) | CEPHEM COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL PREPARATIONS. | |
DE3882438D1 (en) | ALKANSULFONANILIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING THEM. | |
DE3573119D1 (en) | 8-alkylthio-2-piperazino-pyrimidoû5,4-d¨pyrimidines, their preparation and medicaments containing them | |
ZA858030B (en) | Thiadiazole derivatives active on the central nervous system,process for their preparation and pharmaceutical compositions in which they are present | |
ES2027492A6 (en) | 3,4-Di-(hydro)-2H,6H-pyrimido not 2,1-b not 1,3 thiazine derivatives and 1,2,3,4-tetra-(hydro)-pyrimidin-2-thiones, process for their preparation and medicament containing them | |
ES8307798A1 (en) | 1,2,3,4,4a,9b-Hexahydro-4a-piperazinylmethyl-4-dibenzofuranones or substituted 4-dibenzofuranoles, process for their preparation and their therapeutic use. | |
UA27738C2 (en) | 2,3,4,5,6,7-hexahydro-1-(4-(1-(4-(2-methoxyphenyl)piperazinyl))-2-phenylbutyryl)-1h-azepine or pharmaceutically acceptable acid addition salt thereof capable of binding to 5-ht receptors, processes for their preparation (variants) and pharmaceutical composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC1A | Transfer granted |